Premium
5‐Fluorouracil, adriamycin, and mitomycin‐C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas
Author(s) -
Smith Frederick P.,
Hoth Daniel F.,
Levin Bernard,
Karlin David A.,
Macdonald John S.,
Woolley Paul V.,
Schein Philip S.
Publication year - 1980
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19801101)46:9<2014::aid-cncr2820460920>3.0.co;2-d
Subject(s) - medicine , fluorouracil , mitomycin c , regimen , chemotherapy , gastroenterology , adenocarcinoma , toxicity , pancreatic cancer , surgery , oncology , cancer
Thirty‐nine patients with advanced metastatic adenocarcinoma of the pancreas were treated with a combination of 5‐fluorouracil, Adriamycin, and mitomycin‐C (FAM). Twenty‐seven of these patients had measurable disease, and ten (37%) achieved a partial response. An additional three patients had evidence of disease stabilization. The median survival period of responding patients was 12 months, compared with 3.5 months for nonresponders ( P < 0.01). The median survival period for all patients was 6 months. Moderate myelosuppression constituted the treatment‐limiting toxicity. The FAM combination is an active and well‐tolerated regimen for pancreatic cancer and may have an application in the management of patients with less advanced disease.